Welcome to our dedicated page for Structure Therapeutics ADR news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics ADR stock.
Structure Therapeutics Inc. develops oral small-molecule therapeutics for chronic metabolic diseases, with a focus on obesity. The clinical-stage global biopharmaceutical company uses a structure-based drug discovery platform and GPCR-targeted pipeline to advance wholly owned compounds, including aleniglipron, an oral nonpeptide GLP-1 receptor agonist, and ACCG-2671, an oral amylin receptor agonist.
Recurring company updates include clinical data from the ACCESS aleniglipron program, obesity and weight-management research presentations, financial results, research-and-development funding, ADS and warrant financings, and leadership or governance changes. The company’s American depositary shares trade under GPCR, with each ADS representing three ordinary shares.
Structure Therapeutics (NASDAQ: GPCR) will participate in two June 2026 healthcare investor conferences, featuring fireside chats and 1x1 meetings.
Events include the Jefferies Global Healthcare Conference on June 3 in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami, with live and archived webcasts available for 90 days.
Structure Therapeutics (NASDAQ: GPCR) reported Q1 2026 results and a clinical update on May 7, 2026. Key highlights: aleniglipron Phase 2 ACCESS II showed placebo-adjusted weight loss up to 16.3% at 44 weeks; the company received positive end-of-Phase 2 FDA feedback and plans Phase 3 initiation in Q3 2026. Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026, projected to fund operations through end of 2028.
Structure Therapeutics (NASDAQ: GPCR) will present multiple clinical and preclinical posters and an oral presentation at the American Diabetes Association 86th Scientific Sessions, June 5–8, 2026, in New Orleans.
Presentations include ACCESS Phase 2b data reporting meaningful weight reductions, a Phase 2 ACCESS II safety/tolerability poster (doses up to 240 mg), a lower‑starting‑dose GI tolerability analysis, and combination and comparative amylin/GLP‑1 preclinical posters.
Structure Therapeutics (NASDAQ: GPCR) appointed Matthew Lang, J.D. as Chief Operating Officer and General Counsel effective April 14, 2026. Mr. Lang brings 15+ years of global biopharma leadership across legal, corporate strategy, compliance, and business development.
His background includes guiding a company through an up to $10 billion acquisition by Pfizer, leadership roles tied to Phase 3 development and global approvals, and responsibility for ex-US operations; he will support moving aleniglipron into Phase 3 and strengthening operations.
Structure Therapeutics (NASDAQ: GPCR) reported positive Phase 2 ACCESS program topline data for oral GLP-1 receptor agonist aleniglipron. Placebo-adjusted mean weight loss at 44 weeks was -16.3% (180 mg) and -16.0% (240 mg); OLE 56-week loss reached -16.2% (120 mg).
Tolerability improved using a 2.5 mg starting dose (AE-related discontinuations 2.0–3.4%). No drug-induced liver injury or QTc prolongation observed across >625 participants. End-of-Phase 2 FDA meeting set for Q2 2026; Phase 3 initiation on track for 2H 2026.
Structure Therapeutics (NASDAQ: GPCR) reported positive Phase 2 aleniglipron results, including a placebo-adjusted 15.3% weight loss at 36 weeks (240 mg) and no observed weight-loss plateau. The company holds $1.4 billion in cash and short-term investments, expected to fund operations through end-2028.
Topline ACCESS II 44-week results are expected in Q1 2026 and a Phase 3 program is planned to start in 2H 2026; ACCG-2671 entered Phase 1 with data due 2H 2026.
Structure Therapeutics (NASDAQ: GPCR) initiated a first-in-human Phase 1 study of ACCG-2671, an oral once-daily small molecule amylin receptor agonist for the treatment of obesity, on Dec. 17, 2025. ACCG-2671 was designed with the company’s structure-based GPCR drug discovery platform.
Preclinical data reported include potent target engagement, robust weight loss as monotherapy, additional weight loss in combination with a GLP-1 receptor agonist, favorable safety, and PK supporting once-daily dosing. The Phase 1 trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and people with obesity using single-ascending and multiple-ascending dose cohorts.
Structure Therapeutics (NASDAQ: GPCR) closed an upsized underwritten public offering on Dec 11, 2025, selling 9,961,538 ADSs (each ADS = 3 ordinary shares) and pre-funded warrants for 1,538,462 ADSs at $65.00 and $64.9999 respectively.
All securities were sold by the company, including the full exercise of the underwriters' 1,500,000-ADS option, producing gross proceeds of approximately $747.5 million before underwriting discounts, commissions and offering expenses.
Structure Therapeutics (NASDAQ: GPCR) priced an upsized underwritten public offering on Dec 9, 2025 of 8,461,538 ADSs at $65.00 per ADS and pre‑funded warrants for 1,538,462 ADSs at $64.9999. The company expects gross proceeds of approximately $650 million before underwriter fees and expenses. The underwriters have a 30‑day option to buy up to an additional 1,500,000 ADSs. The offering is expected to close on December 11, 2025, subject to customary closing conditions, and is being offered pursuant to an effective Form S‑3 registration statement.
Structure Therapeutics (NASDAQ: GPCR) announced on December 8, 2025 the commencement of a proposed underwritten public offering to issue and sell $500 million of American depositary shares (ADSs) or, for certain investors, pre-funded warrants to purchase ordinary shares represented by ADSs. Each ADS represents three ordinary shares. The company expects to grant underwriters a 30-day option to purchase up to an additional $75 million of ADSs or pre-funded warrants. The offering is subject to market and other conditions and may not be completed. The offering is being made under an automatic shelf registration statement on Form S-3 filed with the SEC on August 6, 2025, and a preliminary prospectus supplement will be filed and available on SEC.gov.